OIG Allows Device Manufacturer to Subsidize Clinical Study Cost-Sharing Amounts
- March 20, 2026
- Written by AHLA Staff
The Department of Health and Human Services Office of Inspector General (OIG) would not impose administrative sanctions on a medical device company that proposes to subsidize certain federal health care program cost-sharing obligations for the purpose of a clinical trial, the agency said in an advisory opinion posted March 16.
ARTICLE TAGS
You must be logged in to access this content.